Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Outcome Definition Influences the Relationship Between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients.

Zazuli Z, Otten LS, Drögemöller BI, Medeiros M, Monzon JG, Wright GEB, Kollmannsberger CK, Bedard PL, Chen Z, Gelmon KA, McGoldrick N, Kitchlu A, Vijverberg SJH, Masereeuw R, Ross CJD, Liu G, Carleton BC, Maitland-van der Zee AH.

Genes (Basel). 2019 May 10;10(5). pii: E364. doi: 10.3390/genes10050364.

2.

Neurotoxicity Among Survivors of Testicular Cancer: A Population-based Study.

Raphael MJ, Wei X, Karim S, Robinson AG, Bedard PL, Booth CM.

Clin Oncol (R Coll Radiol). 2019 May 2. pii: S0936-6555(19)30183-9. doi: 10.1016/j.clon.2019.04.008. [Epub ahead of print]

PMID:
31056287
3.

An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).

Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, Siu LL.

J Immunother Cancer. 2019 Mar 13;7(1):72. doi: 10.1186/s40425-019-0541-0.

4.

Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era.

Tan T, Rheaume M, Wang L, Chow H, Spreafico A, Hansen AR, Razak ARA, Siu LL, Bedard PL.

Oncologist. 2019 Mar 4. pii: theoncologist.2018-0808. doi: 10.1634/theoncologist.2018-0808. [Epub ahead of print]

PMID:
30833487
5.

Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance.

Hamilton RJ, Nayan M, Anson-Cartwright L, Atenafu EG, Bedard PL, Hansen A, Chung P, Warde P, Sweet J, O'Malley M, Sturgeon J, Jewett MAS.

J Clin Oncol. 2019 Feb 25:JCO1801250. doi: 10.1200/JCO.18.01250. [Epub ahead of print]

PMID:
30802156
6.

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.

Rodriguez-Freixinos V, Lheureux S, Mandilaras V, Clarke B, Dhani NC, Mackay H, Butler MO, Wang L, Siu LL, Kamel-Reid S, Stockley T, Bedard PL, Oza AM.

Gynecol Oncol. 2019 May;153(2):304-311. doi: 10.1016/j.ygyno.2019.02.005. Epub 2019 Feb 18.

PMID:
30792002
7.

Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.

Kanjanapan Y, Day D, Wang L, Al-Sawaihey H, Abbas E, Namini A, Siu LL, Hansen A, Razak AA, Spreafico A, Leighl N, Joshua AM, Butler MO, Hogg D, Chappell MA, Soultani L, Chow K, Boujos S, Bedard PL.

Cancer. 2019 Apr 15;125(8):1341-1349. doi: 10.1002/cncr.31999. Epub 2019 Feb 15.

PMID:
30768786
8.

Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.

Shepshelovich D, McDonald K, Spreafico A, Razak ARA, Bedard PL, Siu LL, Minasian L, Hansen AR.

Oncologist. 2019 Apr;24(4):e146-e148. doi: 10.1634/theoncologist.2018-0332. Epub 2019 Feb 6.

PMID:
30728278
9.

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Condorelli R, Mosele F, Verret B, Bachelot T, Bedard PL, Cortes J, Hyman DM, Juric D, Krop I, Bieche I, Saura C, Sotiriou C, Cardoso F, Loibl S, Andre F, Turner NC.

Ann Oncol. 2019 Mar 1;30(3):365-373. doi: 10.1093/annonc/mdz036.

PMID:
30715161
10.

TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses.

Mandilaras V, Garg S, Cabanero M, Tan Q, Pastrello C, Burnier J, Karakasis K, Wang L, Dhani NC, Butler MO, Bedard PL, Siu LL, Clarke B, Shaw PA, Stockley T, Jurisica I, Oza AM, Lheureux S.

Int J Gynecol Cancer. 2019 Jan 18. pii: ijgc-2018-000087. doi: 10.1136/ijgc-2018-000087. [Epub ahead of print]

PMID:
30659026
11.

Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors.

Lewin J, Dufort P, Halankar J, O'Malley M, Jewett MAS, Hamilton RJ, Gupta A, Lorenzo A, Traubici J, Nayan M, Leão R, Warde P, Chung P, Anson Cartwright L, Sweet J, Hansen AR, Metser U, Bedard PL.

JCO Clin Cancer Inform. 2018 Dec;2:1-12. doi: 10.1200/CCI.18.00004.

12.

American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions' Perspectives.

Micheel CM, Sweeney SM, LeNoue-Newton ML, André F, Bedard PL, Guinney J, Meijer GA, Rollins BJ, Sawyers CL, Schultz N, Shaw KRM, Velculescu VE, Levy MA; AACR Project GENIE Consortium.

JCO Clin Cancer Inform. 2018 Dec;2:1-14. doi: 10.1200/CCI.17.00083.

13.

Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels.

Sukhai MA, Misyura M, Thomas M, Garg S, Zhang T, Stickle N, Virtanen C, Bedard PL, Siu LL, Smets T, Thijs G, Van Vooren S, Kamel-Reid S, Stockley TL.

J Mol Diagn. 2019 Mar;21(2):261-273. doi: 10.1016/j.jmoldx.2018.09.008. Epub 2018 Dec 19.

PMID:
30576869
14.

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.

Kanjanapan Y, Day D, Butler MO, Wang L, Joshua AM, Hogg D, Leighl NB, Razak ARA, Hansen AR, Boujos S, Chappell M, Chow K, Sherwin B, Stayner LA, Soultani L, Zambrana A, Siu LL, Bedard PL, Spreafico A.

Eur J Cancer. 2019 Jan;107:1-7. doi: 10.1016/j.ejca.2018.10.017. Epub 2018 Dec 7.

PMID:
30529898
15.

Delivery of chemotherapy for testicular cancer in routine practice: A population-based study.

Karim S, Wei X, Leveridge MJ, Siemens DR, Robinson AG, Bedard PL, Booth CM.

Urol Oncol. 2019 Mar;37(3):183.e17-183.e24. doi: 10.1016/j.urolonc.2018.10.025. Epub 2018 Nov 23.

PMID:
30478011
16.

Sensitive tumour detection and classification using plasma cell-free DNA methylomes.

Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, Zuzarte PC, Borgida A, Wang TT, Li T, Kis O, Zhao Z, Spreafico A, Medina TDS, Wang Y, Roulois D, Ettayebi I, Chen Z, Chow S, Murphy T, Arruda A, O'Kane GM, Liu J, Mansour M, McPherson JD, O'Brien C, Leighl N, Bedard PL, Fleshner N, Liu G, Minden MD, Gallinger S, Goldenberg A, Pugh TJ, Hoffman MM, Bratman SV, Hung RJ, De Carvalho DD.

Nature. 2018 Nov;563(7732):579-583. doi: 10.1038/s41586-018-0703-0. Epub 2018 Nov 14.

PMID:
30429608
17.

Incorporating Genomics Into the Care of Patients With Advanced Breast Cancer.

Kratz J, Burkard M, O'Meara T, Pusztai L, Veitch Z, Bedard PL.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:56-64. doi: 10.1200/EDBK_200731. Review.

PMID:
30231387
18.

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L.

Ann Oncol. 2018 Sep 1;29(9):1895-1902. doi: 10.1093/annonc/mdy263.

PMID:
30137196
19.

Additional germline findings from a tumor profiling program.

Stjepanovic N, Stockley TL, Bedard PL, McCuaig JM, Aronson M, Holter S, Semotiuk K, Leighl NB, Jang R, Krzyzanowska MK, Oza AM, Gupta A, Elser C, Ahmed L, Wang L, Kamel-Reid S, Siu LL, Kim RH.

BMC Med Genomics. 2018 Aug 9;11(1):65. doi: 10.1186/s12920-018-0383-5.

20.

Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor.

Harding JJ, Bauer TM, Tan DSW, Bedard PL, Rodon J, Doi T, Schnell C, Iyer V, Baffert F, Radhakrishnan R, Fabre C, Juric D.

Invest New Drugs. 2019 Apr;37(2):271-281. doi: 10.1007/s10637-018-0627-4. Epub 2018 Aug 3.

21.

Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.

Borges VF, Ferrario C, Aucoin N, Falkson C, Khan Q, Krop I, Welch S, Conlin A, Chaves J, Bedard PL, Chamberlain M, Gray T, Vo A, Hamilton E.

JAMA Oncol. 2018 Sep 1;4(9):1214-1220. doi: 10.1001/jamaoncol.2018.1812.

PMID:
29955792
22.

Lung cancer in never smokers from the Princess Margaret Cancer Centre.

Korpanty GJ, Kamel-Reid S, Pintilie M, Hwang DM, Zer A, Liu G, Leighl NB, Feld R, Siu LL, Bedard PL, Tsao MS, Shepherd FA.

Oncotarget. 2018 Apr 27;9(32):22559-22570. doi: 10.18632/oncotarget.25176. eCollection 2018 Apr 27.

23.

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.

Dickler MN, Saura C, Richards DA, Krop IE, Cervantes A, Bedard PL, Patel MR, Pusztai L, Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, Baselga J.

Clin Cancer Res. 2018 Sep 15;24(18):4380-4387. doi: 10.1158/1078-0432.CCR-18-0613. Epub 2018 May 23.

PMID:
29793946
24.

Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours.

Lewin J, Soltan Ghoraie L, Bedard PL, Hamilton RJ, Chung P, Moore M, Jewett MAS, Anson-Cartwright L, Virtanen C, Winegarden N, Tsao J, Warde P, Sweet J, Haibe-Kains B, Hansen AR.

BJU Int. 2018 Nov;122(5):814-822. doi: 10.1111/bju.14372. Epub 2018 May 31.

PMID:
29726090
25.

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.

Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, Sachdev J, Tourneau CL, van Brummelen EMJ, Varga A, Salgado R, Loi S, Saraf S, Pietrangelo D, Karantza V, Tan AR.

Clin Cancer Res. 2018 Jun 15;24(12):2804-2811. doi: 10.1158/1078-0432.CCR-17-3452. Epub 2018 Mar 20.

PMID:
29559561
26.

Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.

Leão R, van Agthoven T, Figueiredo A, Jewett MAS, Fadaak K, Sweet J, Ahmad AE, Anson-Cartwright L, Chung P, Hansen A, Warde P, Castelo-Branco P, O'Malley M, Bedard PL, Looijenga LHJ, Hamilton RJ.

J Urol. 2018 Jul;200(1):126-135. doi: 10.1016/j.juro.2018.02.068. Epub 2018 Feb 21.

PMID:
29474847
27.

A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.

Leão R, Nayan M, Punjani N, Jewett MAS, Fadaak K, Garisto J, Lewin J, Atenafu EG, Sweet J, Anson-Cartwright L, Boström P, Chung P, Warde P, Bedard PL, Bagrodia A, Freifeld Y, Power N, Winquist E, Hamilton RJ.

Eur Urol Focus. 2018 Dec;4(6):995-1001. doi: 10.1016/j.euf.2018.01.015. Epub 2018 Feb 7.

PMID:
29428550
28.

Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients.

Drögemöller BI, Brooks B, Critchley C, Monzon JG, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Hayden MR, Gelmon KA, Carleton BC, Ross CJD.

Clin Cancer Res. 2018 Apr 15;24(8):1866-1871. doi: 10.1158/1078-0432.CCR-17-2810. Epub 2018 Jan 22.

29.

Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.

Pezo RC, Chen TW, Berman HK, Mulligan AM, Razak AA, Siu LL, Cescon DW, Amir E, Elser C, Warr DG, Sridhar SS, Yu C, Wang L, Stockley TL, Kamel-Reid S, Bedard PL.

Breast Cancer Res Treat. 2018 Feb;168(1):159-168. doi: 10.1007/s10549-017-4580-2. Epub 2017 Nov 24.

30.

Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer.

Ribnikar D, Bedard PL.

Future Oncol. 2017 Dec;13(30):2733-2736. doi: 10.2217/fon-2017-0427. Epub 2017 Nov 23. No abstract available.

31.

Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience.

Chiu JW, Krzyzanowska MK, Serra S, Knox JJ, Dhani NC, Mackay H, Hedley D, Moore M, Liu G, Burkes RL, Brezden-Masley C, Roehrl MH, Craddock KJ, Tsao MS, Zhang T, Yu C, Kamel-Reid S, Siu LL, Bedard PL, Chen EX.

Clin Colorectal Cancer. 2018 Mar;17(1):73-79. doi: 10.1016/j.clcc.2017.10.010. Epub 2017 Oct 23.

PMID:
29128266
32.

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.

Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM.

Clin Cancer Res. 2018 May 1;24(9):2050-2059. doi: 10.1158/1078-0432.CCR-17-2260. Epub 2017 Oct 24.

33.

First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors.

Bédard PL, Davies MA, Kopetz S, Juric D, Shapiro GI, Luke JJ, Spreafico A, Wu B, Castell C, Gomez C, Cartot-Cotton S, Mazuir F, Dubar M, Micallef S, Demers B, Flaherty KT.

Cancer. 2018 Jan 15;124(2):315-324. doi: 10.1002/cncr.31044. Epub 2017 Oct 4.

34.

Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors.

Kwan EM, Beck S, Amir E, Jewett MA, Sturgeon JF, Anson-Cartwright L, Chung PW, Warde PR, Moore MJ, Bedard PL, Tran B.

Clin Genitourin Cancer. 2017 Sep 4. pii: S1558-7673(17)30267-7. doi: 10.1016/j.clgc.2017.08.012. [Epub ahead of print]

PMID:
28943331
35.

Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications.

Shepshelovich D, Goldvaser H, Wang L, Abdul Razak AR, Bedard PL.

Invest New Drugs. 2017 Dec;35(6):827-833. doi: 10.1007/s10637-017-0510-8. Epub 2017 Sep 14. Review.

PMID:
28905282
36.

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.

Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G Jr, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ.

BMC Cancer. 2017 Sep 12;17(1):646. doi: 10.1186/s12885-017-3641-6.

37.

Shrinking Hepatic Hemangiomas in a Patient Treated for Metastatic Germ Cell Tumor.

Barua R, Magony A, Khalili K, Bedard PL, Hansen AR, Lewin J.

Clin Genitourin Cancer. 2017 Aug 31. pii: S1558-7673(17)30249-5. doi: 10.1016/j.clgc.2017.08.008. [Epub ahead of print] No abstract available.

PMID:
28890069
38.

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC.

Clin Cancer Res. 2017 Oct 1;23(19):5687-5695. doi: 10.1158/1078-0432.CCR-17-0900. Epub 2017 Jul 5.

39.

Standard and Genomic Tools for Decision Support in Breast Cancer Treatment.

Henry NL, Bedard PL, DeMichele A.

Am Soc Clin Oncol Educ Book. 2017;37:106-115. doi: 10.14694/EDBK_175617. Review.

40.

AKT Inhibition in Solid Tumors With AKT1 Mutations.

Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS.

J Clin Oncol. 2017 Jul 10;35(20):2251-2259. doi: 10.1200/JCO.2017.73.0143. Epub 2017 May 10. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):360.

41.

Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.

Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Hildebrand CA, Gunaretnam EP, Critchley C, Chen Z, Brunham LR, Hayden MR, Ross CJD, Gelmon KA, Carleton BC.

JAMA Oncol. 2017 Nov 1;3(11):1558-1562. doi: 10.1001/jamaoncol.2017.0502.

42.

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).

Spreafico A, Oza AM, Clarke BA, Mackay HJ, Shaw P, Butler M, Dhani NC, Lheureux S, Wilson MK, Welch S, Zhang T, Yu C, Stockley T, Siu LL, Kamel-Reid S, Bedard PL.

Gynecol Oncol. 2017 Feb;144(2):250-255. doi: 10.1016/j.ygyno.2016.12.002. Epub 2017 Jan 3.

PMID:
28062115
43.

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.

Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao MS, Serra S, Clarke B, Roehrl MH, Zhang T, Sukhai MA, Califaretti N, Trinkaus M, Shaw P, van der Kwast T, Wang L, Virtanen C, Kim RH, Razak AR, Hansen AR, Yu C, Pugh TJ, Kamel-Reid S, Siu LL, Bedard PL.

Genome Med. 2016 Oct 25;8(1):109.

44.

The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours.

Nayan M, Jewett MA, Anson-Cartwright L, Bedard PL, Moore M, Chung P, Warde P, Sweet J, O'Malley M, Hamilton RJ.

Can Urol Assoc J. 2016 May-Jun;10(5-6):204-209.

45.

A Matched Cohort Study of Patients With End-Stage Heart Failure from Anthracycline-Induced Cardiomyopathy Requiring Advanced Cardiac Support.

Thomas GR, McDonald MA, Day J, Ross HJ, Delgado DH, Billia F, Butany JW, Rao V, Amir E, Bedard PL, Thavendiranathan P.

Am J Cardiol. 2016 Nov 15;118(10):1539-1544. doi: 10.1016/j.amjcard.2016.08.020. Epub 2016 Aug 23.

PMID:
27639686
46.

Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer.

Aung KL, Stockley TL, Serra S, Kamel-Reid S, Bedard PL, Siu LL.

Cold Spring Harb Mol Case Stud. 2016 Sep;2(5):a001016. doi: 10.1101/mcs.a001016.

47.

Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer.

Bailey SD, Desai K, Kron KJ, Mazrooei P, Sinnott-Armstrong NA, Treloar AE, Dowar M, Thu KL, Cescon DW, Silvester J, Yang SY, Wu X, Pezo RC, Haibe-Kains B, Mak TW, Bedard PL, Pugh TJ, Sallari RC, Lupien M.

Nat Genet. 2016 Oct;48(10):1260-6. doi: 10.1038/ng.3650. Epub 2016 Aug 29.

48.

Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer.

Nayan M, Jewett MA, Hosni A, Anson-Cartwright L, Bedard PL, Moore M, Hansen AR, Chung P, Warde P, Sweet J, O'Malley M, Atenafu EG, Hamilton RJ.

Eur Urol. 2017 Jan;71(1):120-127. doi: 10.1016/j.eururo.2016.07.013. Epub 2016 Aug 12.

PMID:
27527805
49.

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.

Grilley-Olson JE, Bedard PL, Fasolo A, Cornfeld M, Cartee L, Razak AR, Stayner LA, Wu Y, Greenwood R, Singh R, Lee CB, Bendell J, Burris HA, Del Conte G, Sessa C, Infante JR.

Invest New Drugs. 2016 Dec;34(6):740-749. Epub 2016 Jul 23.

PMID:
27450049
50.

Beta-Testing of Next-Generation DNA Sequencing for Patients With Advanced Cancers Treated at Community Hospitals.

Day D, Bedard PL.

J Oncol Pract. 2016 Apr;12(4):279-81. doi: 10.1200/JOP.2015.010165. Epub 2016 Mar 8. No abstract available.

PMID:
26957640

Supplemental Content

Loading ...
Support Center